China Shineway Pharmaceutical Group Limited (SEHK: 2877) - Valuation on December 13, 2021
China Shineway Pharmaceutical Group Limited (SEHK: 2877) - Valuation on December 13, 2021
The Business Model - Segments, Geographies, and Products
China Shineway Pharmaceutical Group Limited engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China (“PRC”) and Hong Kong. The company started in 1984, went public in 2004, and its headquarters are in Shijiazhuang, China.
The company offers modern Chinese medicines in soft capsules, granules, and injections in various therapeutic areas, including cardio-cerebrovascular, antiviral, orthopaedics, paediatrics, gynaecology, neurology, gastroenterology, ophthalmology, oncology, and immunology. The company operates through five business segments:
Injections: Accounts for 42% of revenues.
Traditional Chinese Medicine (“TCM”) Formula Granules: Accounts for 21% of revenues.
Soft Capsules: Accounts for 17% of revenues.
Granules: Accounts for 15% of revenues.
Other Products: Accounts for 5% of revenues.
